INM InMed Pharmaceuticals Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$1.58

Period return

+0.27 (+20.61%)

Volume

195.4K

2026-06-05O $1.53 H $1.58 L $1.53 C $1.58MA5 $1.56MA20 $1.28MA60 $0.91MA120 $0.98

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

No events to show.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Sector: Healthcare
Industry

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 05. 12.	After market close (AMC)	—	—	—	—	—	Scheduled
FY2026 Q2	2024. 12. 31.	Time TBD	—	$-6.43	—	—	$2.38M	Reported
FY2026 Q1	2024. 09. 30.	Time TBD	—	$-2.71	—	—	$1.26M	Reported
FY2025 Q3	2024. 03. 31.	Time TBD	—	$-16.48	—	—	$3.31M	Reported

InMed Pharmaceuticals Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats